Consequences of Doing What Should Not be Done in Primary Care

Summary

Retrospective observational study in a random selection of 5% of digital records active between 2014 and 2017 to quantify the frequency of Do not do primary care recommendations, calculating the over-cost related to them and study reviewing a random selection of cases previously identified to determine whether patient suffered adverse events and their over-cost.

Conditions

• Overdose
• Adverse Event

Interventions

DRUG

Benzodiazepines

Benzodiazepines for insomnia, agitation or delirium in people older than 65

DRUG

Non-steroidal anti-inflammatory drugs

Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis

DRUG

paracetamol

paracetamol 1g for more than 3 days

DRUG

Antimicrobial agent

antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy

DRUG

Lipid-lowering drug

Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events

DIAGNOSTIC_TEST

Prostate cancer

Screening for prostate cancer in asymptomatic patients

RADIATION

Lumbago

image tests in non-specific lumbago

DRUG

Antimicrobial agent

antibiotics for pharyngitis (infants)

DRUG

Mucolytic

mucolytics, antitussives or antibiotics for upper respiratory infections (infants)

DRUG

Ibuprofen and paracetamol

treatment with ibuprofen and paracetamol (infants)

Sponsors & Collaborators

• Osasunbidea

  collaborator UNKNOWN

• Servicio Madrileño de Salud, Madrid, Spain

  collaborator OTHER

• Fondo de Investigacion Sanitaria

  collaborator OTHER

• AQuAS

  collaborator UNKNOWN

• Agencia de Calidad Sanitaria de Andalucía

  collaborator UNKNOWN

• Ministerio de Sanidad, Servicios Sociales e Igualdad

  collaborator OTHER_GOV

• Servicio Aragones De Salud

  collaborator OTHER

• Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

  collaborator OTHER

• Generalitat Valenciana

  collaborator OTHER

• MurciaSalud

  collaborator OTHER_GOV

• Osakidetza

  collaborator OTHER

• Castilla-La Mancha Health Service

  collaborator OTHER

• Universidad Miguel Hernandez de Elche

  lead OTHER

Principal Investigators

• JOSE J MIRA, PhD · UNIVERSIDAD MIGUEL HERNANDEZ

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-10-14

Primary Completion

2019-12-05

Completion

2020-02-10

Countries

• Spain

Study Locations